feed,title,long_url,short_url
BioRxiv,High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronaviruses,https://biorxiv.org/cgi/content/short/2022.01.17.476672v1?rss=1,https://bit.ly/3rCdKUm
BioRxiv,Differences in environmental stability among SARS-CoV-2 variants of concern: Omicron has higher stability,https://biorxiv.org/cgi/content/short/2022.01.18.476607v1?rss=1,https://bit.ly/3GGSaV8
BioRxiv,"Nirmatrelvir, Molnupiravir, and Remdesivir maintain potent in vitro activity against the SARS-CoV-2 Omicron variant",https://biorxiv.org/cgi/content/short/2022.01.17.476685v1?rss=1,https://bit.ly/3fF5Yn4
BioRxiv,Prediction and validation of host cleavage targets of SARS-CoV-2 3C like protease,https://biorxiv.org/cgi/content/short/2022.01.17.476677v1?rss=1,https://bit.ly/3tJ3AUA
